-
公开(公告)号:NO20005301D0
公开(公告)日:2000-10-20
申请号:NO20005301
申请日:2000-10-20
Applicant: ABBOTT LAB
Inventor: MARING CLARENCE J , GU YU-GUI , CHEN HUI-JU , CHEN YUANWEI , DEGOEY DAVID A , FLOSI WILLIAM J , GIRANDA VINCENT L , GRAMPOVNIK DAVID J , KATI WARREN M , KEMPF DALE J , KLEIN LARRY L , KRUEGER ALLAN C , LIN ZHEN , MADIGAN DAROLD L , MCDANIEL KEITH F , MUCHMORE STEVEN W , SHAM HING L , STEWART KENT D , STOLL VINCENT S , SUN MINGHUA , WANG GARY T , WANG SHELDON , XU YIBO , YEUNG MING C , ZHAO CHEN , KENNEDY APRIL
IPC: A61K31/401 , A61K31/4025 , A61K31/41 , A61K31/4155 , A61K31/4178 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/433 , A61K31/5377 , A61P31/16 , A61P43/00 , C07D207/16 , C07D207/32 , C07D207/325 , C07D207/327 , C07D401/12 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D405/14 , C07D409/04 , C07D409/06 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/06 , C07D521/00 , C07F9/572 , C07D
-
公开(公告)号:AU3554599A
公开(公告)日:1999-11-08
申请号:AU3554599
申请日:1999-04-12
Applicant: ABBOTT LAB
Inventor: MARING CLARENCE J , GU YU-GUI , CHEN HUI-JU , CHEN YUANWEI , DEGOEY DAVID A , FLOSI WILLIAM J , GIRANDA VINCENT L , GRAMPOVNIK DAVID J , KATI WARREN M , KEMPF DALE J , KLEIN LARRY L , KRUEGER ALLAN C , LIN ZHEN , MADIGAN DAROLD L , MCDANIEL KEITH F , MUCHMORE STEVEN W , SHAM HING L , STEWART KENT D , STOLL VINCENT S , SUN MINGHUA , WANG GARY T , WANG SHELDON , XU YIBO , YEUNG MING C , ZHAO CHEN , KENNEDY APRIL
IPC: A61K31/401 , A61K31/4025 , A61K31/41 , A61K31/4155 , A61K31/4178 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/433 , A61K31/5377 , A61P31/16 , A61P43/00 , C07D207/16 , C07D207/32 , C07D207/325 , C07D207/327 , C07D401/12 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D405/14 , C07D409/04 , C07D409/06 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/06 , C07D521/00 , C07F9/572 , A61K31/40 , C07D407/04
-
公开(公告)号:CA2504385C
公开(公告)日:2012-12-18
申请号:CA2504385
申请日:2003-10-31
Applicant: ABBOTT LAB
Inventor: PRATT JOHN K , BETEBENNER DAVID A , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , MCDANIEL KEITH F , MARING CLARENCE J , STOLL VINCENT S , ZHANG RONG
IPC: C07D495/04 , A61K31/554 , A61P31/00 , C07D213/69 , C07D215/22 , C07D401/04 , C07D417/04 , C07D417/14 , C07D471/04 , C07D513/04 , C07D513/14 , C07D519/00
Abstract: The present invention provides an HCV polymerase inhibiting compound having the formula (I) and a composition comprising a therapeutically effective amount of said compound. The present invention also provides a method for inhibiting hepatitis C virus (HCV) polymerase, a method for inhibiting HCV viral replication, and a method for treating or preventing HCV infection. Processes for making said compounds, and synthetic intermediates employed in said processes, are also provided.
-
公开(公告)号:DK1560827T3
公开(公告)日:2011-04-18
申请号:DK03768559
申请日:2003-10-31
Applicant: ABBOTT LAB
Inventor: PRATT JOHN K , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , MCDANIEL KEITH F , MARING CLARENCE J , STOLL VINCENT S , BETEBENNER DAVID A , ZHANG RONG
IPC: C07D471/04 , A61K31/554 , A61P31/00 , C07D213/69 , C07D215/22 , C07D401/04 , C07D417/04 , C07D417/14 , C07D495/04 , C07D513/04 , C07D513/14 , C07D519/00
-
公开(公告)号:DE60335564D1
公开(公告)日:2011-02-10
申请号:DE60335564
申请日:2003-10-31
Applicant: ABBOTT LAB
Inventor: PRATT JOHN K , BETEBENNER DAVID A , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , MCDANIEL KEITH F , MARING CLARENCE J , STOLL VINCENT S , ZHANG RONG
IPC: C07D471/04 , A61K31/554 , A61P31/00 , C07D213/69 , C07D215/22 , C07D401/04 , C07D417/04 , C07D417/14 , C07D495/04 , C07D513/04 , C07D513/14 , C07D519/00
-
公开(公告)号:BR0315897A
公开(公告)日:2008-05-13
申请号:BR0315897
申请日:2003-10-31
Applicant: ABBOTT LAB
Inventor: PRATT JOHN K , BETEBENNER DAVID A , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , MCDANIEL KEITH F , MARING CLARENCE J , STOLL VINCENT S , ZHANG RONG
IPC: C07D471/04 , A61K31/554 , A61P31/00 , C07D213/69 , C07D215/22 , C07D401/04 , C07D417/04 , C07D417/14 , C07D495/04 , C07D513/04 , C07D513/14 , C07D519/00
Abstract: The present invention provides an HCV polymerase inhibiting compound having the formula (I) and a composition comprising a therapeutically effective amount of said compound. The present invention also provides a method for inhibiting hepatitis C virus (HCV) polymerase, a method for inhibiting HCV viral replication, and a method for treating or preventing HCV infection. Processes for making said compounds, and synthetic intermediates employed in said processes, are also provided. formula (I)
-
公开(公告)号:PL376823A1
公开(公告)日:2006-01-09
申请号:PL37682303
申请日:2003-10-31
Applicant: ABBOTT LAB
Inventor: PRATT JOHN K , BETEBENNER DAVID A , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , MCDANIEL KEITH F , MARING CLARENCE J , STOLL VINCENT S , ZHANG RONG
IPC: C07D471/04 , A61K31/554 , A61P31/00 , C07D213/69 , C07D215/22 , C07D401/04 , C07D417/04 , C07D417/14 , C07D495/04 , C07D513/04 , C07D519/00
-
公开(公告)号:AU2003291670A1
公开(公告)日:2004-06-07
申请号:AU2003291670
申请日:2003-10-31
Applicant: ABBOTT LAB
Inventor: PRATT JOHN K , BETEBENNER DAVID A , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , MCDANIEL KEITH F , MARING CLARENCE J , STOLL VINCENT S , ZHANG RONG
IPC: A61P31/00 , C07D213/69 , C07D215/22 , C07D401/04 , C07D417/04 , C07D417/14 , C07D471/04 , C07D495/04 , C07D513/04 , C07D519/00 , C07D513/14 , A61K31/554
Abstract: The present invention provides an HCV polymerase inhibiting compound having the formula (I) and a composition comprising a therapeutically effective amount of said compound. The present invention also provides a method for inhibiting hepatitis C virus (HCV) polymerase, a method for inhibiting HCV viral replication, and a method for treating or preventing HCV infection. Processes for making said compounds, and synthetic intermediates employed in said processes, are also provided. formula (I)
-
公开(公告)号:CA2470214A1
公开(公告)日:2003-06-26
申请号:CA2470214
申请日:2002-12-12
Applicant: ABBOTT LAB
Inventor: HUTCHINS CHARLES , GIRANDA VINCENT L , GONG JIANCHUN , STOLL VINCENT S , ABRAMS JASON N , DINGES JURGEN , ZHU GUI-DONG , DIEBOLD ROBERT , SONG XIAOHONG , ROSENBERG SAUL H , FISCHER JOHN P , LI QUN , GANDHI VIRAJ , WOODS KEITH W , PACKARD GARRICK , THOMAS SHEELA A , LI TONGMEI
IPC: C07D239/48 , A61K31/416 , A61K31/4365 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/455 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/502 , A61K31/505 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/52 , A61K31/5377 , A61P35/00 , A61P43/00 , C07D213/63 , C07D213/65 , C07D213/75 , C07D213/82 , C07D231/56 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D473/34 , C07D475/02 , C07D495/04 , C07D498/04
Abstract: Compounds having the formula (I), are useful for inhibiting protein kinases and for the treatment of cancer. Also disclosed are compositions which inhib it protein kinases and methods of inhibiting protein kinases in a patient.
-
公开(公告)号:CO5271741A1
公开(公告)日:2003-04-30
申请号:CO00079304
申请日:2000-10-18
Applicant: ABBOTT LAB
Inventor: MARRING CLARENCE J , GIRANDA VINCENT L , WARREN M KATI , KRUEGER ALLAN C , MUCHMORE STEVEN W , STOLL VINCENT S , SHELDON WANG , YUANWEI CHEN , GRAMPOVNIK DAVID J , KEMPF DALE J , ZHEN LIN , MINGHUA SUN , MING C YEUNG , DEGOEY DAVID A , YU GUI GU , APRIL L KENNEDY , MADIGAN DONALD L , KENT D STEWART , WANG GARY T , CHEN ZHAO
IPC: A61K31/16 , A61K31/18 , A61K31/195 , A61K31/341 , A61K31/381 , C07C233/48 , C07C237/24 , C07C271/22 , C07C271/24 , C07C279/16 , C07D233/54 , C07D263/32 , C07D307/24 , C07D317/30 , C07D405/04
Abstract: Un compuesto enantioméricamente enriquecido CARACTERIZADO PORQUE tiene la estereoquímica absoluta de fórmula o una sal, éster o una prodroga de los mismos,donde R1 se selecciona del grupo formado por(a) -CO2H, (b) -CH2CO2H, (c) -SO3H, (d) -CH2SO3H, (e) -SO2H, (f) -CH2SO2H, (g)-PO3H2, (h) -CH2PO3H2, (i) -PO2H, (j) -CH2PO2H, (k) tetrazolilo, (l) -CH2-tetrazolilo, (m) -C(=O)-NH-S(O)2-R11, (n) -CH2C(=O)-NH-S(O)2-R11, (o) -SO2N(T-R11)R12 y (p) -CH2SO2N(T-R11 )R12donde T se selecciona del grupo formado por(i) un enlace, (ii) -C(=O)-, (iii) -C(=O)O-, (iv) -C(=O)S-, (v) -C(O)NR36, (vi) -C(=S)O-, (vii) -C(=S)S- y (viii) -C(=S)NR36-,R11 se selecciona del grupo formado por(i) C1-C12-alquilo, (ii) C2-C12-alquenilo, (iii) cicloalquilo, (iv) (cicloalquil)alquilo, (v) (cicloalquil)alquenilo, (vi) cicloalquenilo, (vii) (cicloalquenil)alquilo, (viii) (cicloalquenil)alquenilo, (ix) arilo, (x) (aril)alquilo, (xi) (aril)alquenilo, (xii) heterocíclico, (xiii) alquilo(heterocíclico) y (xiii) (xiv) alquenilo(heterocíclico); yR12 y R36 se seleccionan, independientemente entre sí, del grupo formado por - 2 -(i) hidrógeno, (ii) C1-C12-alquilo, (iii) C2-C12-alquenilo, (iv) cicloalquilo, (v) (cicloalquil)alquilo, (vi) (cicloalquil)alquenilo, (vii) cicloalquenilo, (viii) (cicloalquenil)alquilo, (ix) (cicloalquenil)alquenilo, (x) arilo, (xi) (aril)alquilo, (xii) (aril )alquenilo, (xiii) heterocíclico, (xiv) alquilo(heterocíclico) y (xv) alquenilo(heterocíclico);X se selecciona del grupo formado por(a) -C(=O)-N(R*)-, (b) -N(R*)-C(=O)-, (c) -C(=S)-N(R*)-, (d) -N(R*)-C(=S)-, (e) -N(R*)-SO2-, y M -SO2-N(R*)-, donde R* es hidrógeno, C1-C3-alquilo inferior o ciclopropilo;R2 se selecciona del grupo formado por(a) hidrógeno, (b) C1-C6-alquilo, (C) C2-C6-alquenilo, (d) C3-C6-cicloalquilo, (e) C5-C6-cicloalquenilo, (f) halo-C1-C6-alquilo y (g) halo-C2-C6-alquenilo;o R2-X es donde Y1 es -CH2-, -O-, -S- o -NH- e Y2 es -C(=O)- o -C(Raa)(Rbb), donde Raa y Rbb se seleccionan, independientemente entre sí, del grupo formado por hidrógeno, C1-C3-alquilo inferior, hidroximetilo, 1-hidroxietilo, 2-hidroxietilo, aminometilo, 1-aminoetilo, 2-aminoetilo, tiolmetilo, 1-tioletilo, 2-tioletilo, metoximetilo, N-metilaminometilo y metiltiometilo;Z1 es -O-, -S-, or C(R5)2;R3 y R4 se seleccionan, independientemente entre sí, del grupo formado por (a) hidrógeno, (b) cicloalquilo, (c) cicloalquenilo, (d) heterocíclico, (e) arilo y (f) -Z-R14donde Z es(i) -C(R37a)(R37b)-, (ii) -C(R47)=C(R48)-, (iii) -C=C-, (iv) -C(=O)- (v) -C(=S)-, (vi) -C(=NR15)-, (vii) -C(R37a)-C(OR37c)-, (viii) -C(R37a)(SR37c)-, (ix)-C(R37a)(N(R37b)(R37c))-, (x) -C(R37a)(R37b)-O-, (xi)-C(R37a)(R37b)-N(R37c)-, (xii) -C(R37a)(R37b)-N(O)(R37c), (xiii) -C(R37a)(R37b)-N(OH)-, (xiv) -C(R37a)(R37b)-S-, (xv) -C(R37a)(R37b)-S(O)-, (xvi) -C(R37a)(R37b)-S(O)2-, (xvii) -C(R37a)(R37b)-C(=O)-, (xviii) -C(R37a)(R37b)-C(=S)-, (xix) -C(R37a)(R37b)-C(=NR15)-, (xx) -C(R37a)(OR37c)-C(=O)-, (xxi) -C(R37a)(SR37b)-C(=O)-, (xxii) -C(R37a)(OR37c)-C(=S)-, (xxiii) -C(R37a)(SR37c)-C(=S)-, (xxiv) -C(=O)-C(R37a)(OR37c)-, (xxv) -C(=O)-C(R37a)(SR37c)-, (xxvi) -C(=S)-C(R37a)(OR37c)-, (xxvii)-C(=S)-C(R37a)(SR37c)-, (xxviii) -C(R37a)(OR37c)-C(R37a)(OR37c)-, (xxix) -C(R37a)(SR37c)-C(R37a)(OR37c)-, (xxx) -C(R37a)(OR37c)-C(R37a)(SR37c)-, (xxxi) -C(R37a)(SR37c)-C(R37a)(SR37c)-, (xxxii) -C(=O)-C(=O)-, (xxxiii) -C(=S)-C(=S)-, (xxxiv)-C(=O)-O-, (xxxv) -C(=O)-S-, (xxxvi) -C(=S)-O-, (xxxvii) -C(=S)-S-, (xxxviii) -C(=O)-N(R37a)- (xxxix) -C(=S)-N(R37a)-, (xl)-C(R37a)(R37b)-C(=O)-N(R37a)-, (xli) -C(R37a)(R37b)-C(=S)-N(R37a)-, (xlii) -C(R37a)(R37b)-C(=O)-O-, (xliii) -C(R37a)(R37b)-C(=O)-S-, (xliv) -C(R37a)(R37b)-C(=S)-O-, (xlv) -C(R37a)(R37b)-C(=S)-S-, (xlvi)-C(R37a)(R37b)-N(R37b)-C(=O)-, (xlvii) -C(R37a)(R37b)-N(R37b)-C(=S)-, (xlviii)-C(R37a)(R37b)-O-C(=O)-, (xlix) -C(R37a)(R37b)-S-C(=O)-, (I) -C(R37a)(R37b)-O-C(=S)-, (li) -C(R37a)(R37b)-S-C(=S)-, (lii) -C(R37a)(R37b)-N(R37b)-C(=O)-N(R37a) (liii) -C(R37a)(R37b)-N(R37b)-C(=S)-N(R37a)-, (liv) -C(R37a)(R37b)-N(R37b)-C(=O)-O-, (lv) -C(R37a)(R37b)-N(R37b)-C(=O)-S-, (lvi) -C(R37a)(R37b)-N(R37b)-C(=S)-O- (lvii) -C(R37a)(R37b)-N(R37b)-C(=S)-S-, (lviii) -C(R37a)(R37b)-O-C(=O)-N(R37a)-, (lix) -C(R37a)(R37b)-S-C(=O)-N(R37a), (Ix) -C(R37a)(R37b)-O-C(=S)-N(R37a)-, (lxi) -C(R37a)(R37b)-S-C(=S)-N(R37a), (lxii) -C(R37a)(R37b)-O-C(=O)-O-, (lxiii) -C(R37a)(R37b)-S-C(=O)-O, (lxiv) -C(R37a)(R37b)-O-C(=O)-S-, (lxv) -C(R37a)(R37b)-S-C(=O)-S-, (lxvi) -C(R37a)(R37b)-O-C(=S)-O-, (lxvii) -C(R37a)(R37b)-S-C(=S)-O-, (lxviii) -C(R37a)(R37b)-O-C(=S)-S-, (lxix) -C(R37a)(R37b)-S-C(=S)-S-, o (lxx) -C(R37a)(R37b)-C(R37a)(OR37c);R14 es(i) hidrógeno, (ii) C1-C12-alquilo, (iii) haloalquilo, (iv) hidroxialquilo, (v) alquilotiol-sustituido, (vi) alquilo R37c-O-sustituido, (vii) alquilo R37c-S-sustituido, (viii) aminoalquilo, (ix) alquilo (R37c)NH-sustituido, (x) alquilo(R37a)(R37c)N-sustituido, (xi) alquilo R37a -O-(O=)C-sustituido, (xii) alquilo R37a-S-(O=)C-sustituido, (xiii) alquiloR37aO-(S=)C-sustituido, (xiv) alquilo R37a-S-(S=)C-sustituido, (xv) alquilo (R37aO)2-P(=O)-sustituido, (xvi) cianoalquilo, (xvi) C2-C12-alquenilo, (xviii) haloalquenilo, (xix) C2-C12-alquinilo,(xx) cicloalquilo, (xxi) (cicloalquil)alquilo, (xxii) (cicloalquil)alquenilo, (xxiii) (cicloalquil)alquinilo, (xxiv) cicloalquenilo, (xxv) (cicloalquenil)alquilo, (xxvi) (cicloalquenil)alquenilo, (xxvii) (cicloalquenil)alquinilo, (xxviii) arilo, (xxix) (aril)alquilo, (xxx) (aril)alquenilo, (xxxi) (aril)alquinilo, (xxxii) heterocíclico, (xxxiii) alquil(heterocíclico), (xxxiv) alquenil(heterocíclico) o (xxxv) alquinil(heterocíclico),con la condición que es distinto de hidrógeno cuando Z es-C(R37a)(R37b)-N(R37b)-C(=O)-O-, -C(R37a)(R37b)-N(R37b)-C(=S)-O-, -C(R37a)(R37b)-N(R37b)-C(=O)-O-, -C(R37a)(R37b)-N(R37b)-C(=S)-S-, - 3 --C(R37a)(R37b)-O-C(=O)-O-, -C(R37a)(R37b)-O-C(=S)-O-, -C(R37a)(R37b)-S-C(=O)-O-, -C(R37a)(R37b)-S-C(=S)-O-, -C(R37a)(R37b)-O-C(=O)-S-, -C(R37a)(R37b)-O-C(=S)-S-, -C(R37a)(R37b)-S-C(=O)-S o -C(R37a)(R37b)-S-C(=S)-S-; R37a, R37b y R37c, se seleccionan en cada aparición, independientemente entre sí, del grupo formado por(i) hidrógeno, (ii) C1-C12-alquilo, (iii) haloalquilo, (iv) hidroxialquilo, (v) alcoxialquilo, (vi) C2-C12-alquenilo, (vii) haloalquenilo, (viii) C2-C12-alquinilo, (ix) cicloalquilo, (x)(cicloalquil)alquilo, (xi) (cicloalquil)alquenilo, (xii) (cicloalquil)alquinilo, (xiii) cicloalquenilo, (xiv) (cicloalquenil)alquilo, (xv) (cicloalquenil)alquenilo, (xvi) (cicloalquenil)alquinilo, (xvii) arilo, (xviii) (aril)alquilo, (xix) (aril)alquenilo, (xx) (aril)alquinilo, (xxi) heterocíclico, (xxii) alquil(heterocíclico), (xxiii) alquenil(heterocíclico) y (xxiv) alquinil(heterocíclico),R37c se selecciona en cada aparición, independientemente, del grupo formado por: (i) hidrógeno, (ii) C1-C12-alquilo, (iii) haloalquilo, (iv) C2-C12-alquenilo, (v) haloalquenilo, (vi) C2-C12-alquinilo, (vii) cicloalquilo, (viii) (cicloalquil)alquilo, (ix) (cicloalquil)alquenilo, (x) (cicloalquil)alquinilo, (xi) cicloalquenilo, (xii) (cicloalquenil)alquilo, (xiii) (cicloalquenil)alquenilo, (xiv) (cicloalquenil)alquinilo, (xv) arilo, (xvi) (aril)alquilo, (xvii) (aril)alquenilo, (xviii) (aril)alquinilo, (xix) heterocíclico, (xx) alquilo(heterocíclico), (xxi) alquenilo(heterocíclico) (xxii) alquinilo(heterocíclico), (xxiii) -C(=O)-R14, y (xxiv) -C(=S)-R, (xxv) -S(O)2-R14 y (xxvi) hidroxialquilo;o cuando Z es -C(R37a)(R37b)-N(R37c)-, entonces cuando N(R37C)-R14 se toman juntos constituyen un grupo azida;o cuando Z es -C(R37a)(R37b)-N(O)(R37c)-, entonces cuando N(O)(R37C)-R14 se toman juntos constituyen un anillo heterocíclico de 3-7 miembros N-oxidado que posee por lo menos un átomo de nitrógeno en el anillo N-oxidado,o cuando Z es -C(R37a)(OR37c)-, -C(R37a)(SR37c)- o - -C(R37a)(N(R37b)(R37c))-, luego R37a, R14 y el átomo de carbono al que estaban unidos cuando se toman juntos forman un anillo ciclopentilo, ciclopentenilo, ciclohexilo o ciclohexenilo o luego OR37c o SR37c o N(R37c) y R14 y el átomo de carbono al que están unidos cuando se toman juntos forman un anillo heterocíclico que contiene un átomo de O, S o N, respectivamente, y conteniendo desde 4 a 8 átomos del anillo;R15 se selecciona del grupo formado por(i) hidrógeno, (ii) hidroxi, (iii) amino, (iv) C1-C12-alquilo, (v) haloalquilo, (vi) C2-C12-alquenilo, (vii) haloalquenilo, (viii) cicloalquilo, (ix) (cicloalquil)alquilo, (x) (cicloalquil)alquenilo, (xi) cicloalquenilo, (xii) (cicloalquenil)alquilo, (xiii) (cicloalquenil)alquenilo, (xiv) arilo, (xv) (aril)alquilo, (xvi) (aril)alquenilo, (xvii) heterocíclico, (xviii) alquilo(heterocíclico) y (xix) alquenilo(heterocíclico),o R3 y R4 tomados juntos, con el átomo al cual están unidos, forman un anillo carbocíclico o heterocíclico que posee de 3 a 8 átomos en el anillo;R5 en cada aparición, se selecciona independientemente del grupo formado por:(a) hidrógeno, (b) -CH(R38)2, (c) -(CH2)r-O-R40, (d) C2-C4 alquinilo, (e) ciclopropilo, (f) ciclobutilo, (g) -C(=Q1)-R17, y (h) -(CH2)rN(R19)2donde r es 0, 1 ó 2; con la condición que cuando un R5 es -O-R40 o -N(R19)2, entonces el otro R5 es diferente que -O-R40 o -N(R19)2; donde Q1 es O, S o N(R18);R17 y R18 se seleccionan independientemente, en cada aparición, del grupo formado por hidrógeno, metilo y etilo;R19 , R38 y R40 se seleccionan independientemente, en cada aparición, del grupo formado por(i) hidrógeno, (ii) C1-C12-alquilo, (iii) haloalquilo, (iv) C2-C12-alquenilo, (v) haloalquenilo, (vi) cicloalquilo, (vii) (cicloalquil)alquilo, (viii) (cicloalquil)alquenilo, (ix) cicloalquenilo, (x) (cicloalquenil)alquilo, (xi) (cicloalquenil)alquenilo, (xii) arilo, (xiii) (aril)alquilo, (xiv) (aril)alquenilo, (xv) heterocíclico, (xvi) alquilo(heterocíclico) y (xvii) alquenilo(heterocíclico); o un R19 es un grupo N-protector;o los dos grupos R5 se toman juntos con un átomo de carbono al cual están unidos, forman un anillo carbocíclico o heterocíclico q
-
-
-
-
-
-
-
-
-